Friday, 16 October 2026European Markets

SALMONES CAMANCHAC Stock Was Up By 16.5% On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with SALMONES CAMANCHAC (SACAM.OL) rising 16.5% to kr24.00 on Tuesday while Oslo Børs Benchmark Index_GI dropped 2.2% to kr1,397.48.

SALMONES CAMANCHAC's last close was kr20.60, 51.42% below its 52-week high of kr42.40.

About SALMONES CAMANCHAC

Salmones Camanchaca S.A. engages in the salmon farming business in Chile. The company offers Atlantic and Coho salmon products in various formats, such as whole, fillet, portion, and other products including bits and pieces, harasu, and scrape meat. It also exports its products. Salmones Camanchaca S.A. was incorporated in 2009 and is based in Puerto Montt, Chile. Salmones Camanchaca S.A. (SNSE:SALMOCAM) operates as a subsidiary of Camanchaca S.A. (SNSE:CAMANCHACA).

Earnings Per Share

As for profitability, SALMONES CAMANCHAC has a trailing twelve months EPS of kr-0.87.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -7.32%.

Yearly Top and Bottom Value

SALMONES CAMANCHAC's stock is valued at kr24.00 at 22:31 EST, way below its 52-week high of kr42.40 and way higher than its 52-week low of kr13.60.

Volatility

SALMONES CAMANCHAC's last week, last month's, and last quarter's current intraday variation average was 0.33%, 1.15%, and 8.42%.

SALMONES CAMANCHAC's highest amplitude of average volatility was 8.17% (last week), 11.42% (last month), and 8.42% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SALMONES CAMANCHAC's stock is considered to be overbought (>=80).

Sales Growth

SALMONES CAMANCHAC's sales growth is 70.5% for the ongoing quarter and 17.2% for the next.

More news about SALMONES CAMANCHAC (SACAM.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com